DE60312997D1 - Nf-kb-inhibitoren - Google Patents

Nf-kb-inhibitoren

Info

Publication number
DE60312997D1
DE60312997D1 DE60312997T DE60312997T DE60312997D1 DE 60312997 D1 DE60312997 D1 DE 60312997D1 DE 60312997 T DE60312997 T DE 60312997T DE 60312997 T DE60312997 T DE 60312997T DE 60312997 D1 DE60312997 D1 DE 60312997D1
Authority
DE
Germany
Prior art keywords
kappab
inhibitors
diseases
activation
aminothiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60312997T
Other languages
English (en)
Other versions
DE60312997T2 (de
Inventor
James F Callahan
Zehong Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of DE60312997D1 publication Critical patent/DE60312997D1/de
Application granted granted Critical
Publication of DE60312997T2 publication Critical patent/DE60312997T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
DE60312997T 2002-06-06 2003-05-29 Nf-kb-inhibitoren Expired - Fee Related DE60312997T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38655702P 2002-06-06 2002-06-06
US386557P 2002-06-06
PCT/US2003/016876 WO2003104219A1 (en) 2002-06-06 2003-05-29 Nf-kb inhibitors

Publications (2)

Publication Number Publication Date
DE60312997D1 true DE60312997D1 (de) 2007-05-16
DE60312997T2 DE60312997T2 (de) 2007-12-13

Family

ID=29736178

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60312997T Expired - Fee Related DE60312997T2 (de) 2002-06-06 2003-05-29 Nf-kb-inhibitoren

Country Status (8)

Country Link
US (1) US7300952B2 (de)
EP (1) EP1532135B1 (de)
JP (1) JP2005532359A (de)
AT (1) ATE358673T1 (de)
AU (1) AU2003240935A1 (de)
DE (1) DE60312997T2 (de)
ES (1) ES2285125T3 (de)
WO (1) WO2003104219A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
AU2005238178A1 (en) * 2004-05-04 2005-11-10 F. Hoffmann-La Roche Ag Thienopyridazines as IKK inhibitors
AU2005238180A1 (en) * 2004-05-04 2005-11-10 F. Hoffmann-La Roche Ag Thienopyridines as IKK inhibitors
US7812018B2 (en) 2006-02-16 2010-10-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
WO2008069102A1 (ja) * 2006-12-06 2008-06-12 Calpis Co., Ltd. 炎症性腸疾患予防治療剤
BRPI0919282A2 (pt) 2008-10-02 2017-03-28 Asahi Kasei Pharma Corp composto, composição farmacêutica, inibidor de ikkb, método para inibir ikkb, métodos para prevenir e/ou tratar uma doença ou sintoma associado com nf-kb, uma doença ou sintoma associado com ikkb, e uma doença ou sintoma associado com reação inflamatória aguda ou crônica em mamíferos
WO2013118842A1 (ja) * 2012-02-09 2013-08-15 国立大学法人東京医科歯科大学 ベンゾチオフェン化合物、該化合物を有効成分とするオルタナティブオートファジー誘導剤及び抗癌剤、並びに抗癌活性を有する化合物をスクリーニングするための方法
US20170240522A1 (en) * 2014-09-15 2017-08-24 École Polytechnique Fédérale De Lausanne (Epfl) Benzothiophene, benzyloxybenzylidene and indoline derivatives useful for the treatment of tuberculosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782080A (en) * 1985-09-16 1988-11-01 Merck & Co., Inc. N-alkenyl-2-hydroxybenzo(b)thiophene-3-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
EP0979076A4 (de) * 1997-04-30 2003-03-19 Lilly Co Eli ZWISCHENPRODUKTE UND VERFAHREN ZUR HERSTELLUNG VON BENZO b]-THIOPHENEN
EP1324759A4 (de) 2000-10-12 2004-05-12 Smithkline Beecham Corp Nf--g(k)b inhibitoren

Also Published As

Publication number Publication date
US20060058371A1 (en) 2006-03-16
EP1532135B1 (de) 2007-04-04
JP2005532359A (ja) 2005-10-27
US7300952B2 (en) 2007-11-27
EP1532135A1 (de) 2005-05-25
ATE358673T1 (de) 2007-04-15
AU2003240935A1 (en) 2003-12-22
WO2003104219A1 (en) 2003-12-18
ES2285125T3 (es) 2007-11-16
EP1532135A4 (de) 2005-11-09
DE60312997T2 (de) 2007-12-13

Similar Documents

Publication Publication Date Title
DE60229975D1 (de) Nf-kb-inhibitoren
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
SE0203752D0 (sv) New compounds
MA28176A1 (fr) Inhibiteurs de la forme mutante du kit
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
DE60312997D1 (de) Nf-kb-inhibitoren
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
DE60329326D1 (de) Tace inhibitoren
WO2003086309A3 (en) NF-κB INHIBITORS
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE486598T1 (de) Kinase inhibitoren und deren verwendung
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
DE50200635D1 (de) Verwendung von inhibitoren von ikk-beta und verfahren zum auffinden solcher inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee